Dr Reddy's extends slide as semaglutide supply snag raises earnings risks
10/07/2026 04:49
Dr Reddy's extends slide as semaglutide supply snag raises earnings risks July 10 (Reuters) - Shares of Dr Reddy's Laboratories REDY.NS slipped 3% on Friday, extending losses from the previous session, after a disruption in the supply of its generic semaglutide fuelled fears of delayed commercialisation and prompted analysts to flag earnings risks and a potential loss of first-mover advantage.
The stock was trading at 1,230 rupees, and was the top loser on the pharma index .NIPHARM which was down 0.6%.
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.Tandon@thomsonreuters.com; 8800437922;))
Recent news on Dr. Reddy's Laboratories
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Dr Reddy's beats quarterly profit estimate on India market lift (updated)
India's Dr Reddy's beats quarterly profit estimate
Brief: Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption